Studies were performed in 20 patients with breast cancer, who received 26 cycles of high-dose cisplatin (100 mg/m2, IV. drip). In twenty-five cycles of them urinary Alb, IgG and NAG showed abnormal values. The patient...Studies were performed in 20 patients with breast cancer, who received 26 cycles of high-dose cisplatin (100 mg/m2, IV. drip). In twenty-five cycles of them urinary Alb, IgG and NAG showed abnormal values. The patients were divided into low-nephrotoxicity and high-nephrotoxicity groups by the degree of renal dysfunction. Thirty-five percent of the patients exhibited high-nephrotoxicity. These patients had significantly higher plasma and/ or urinary Pt peak levels during cisplatin (CP) infusion than did low-nephrotoxicity. 70 - 80% of the patients developed significant nephrotoxicity when urinary Pt peak level rose up to 40 fig/ml or plasma Pt peak level >4 μg/ml. It is quite important to reduce nephrotoxicity that urinary Pt level is controlled below 40 μg/ml and plasma Pt level <4 μg/ml. It is suggested that urine output should be maintained over 300 ml/hr during 2 hours before and after the end of infusion and >100 ml/hr during 3 days after the infusion. That may keep the nephrotoxicity of CP in less serious degree and easy to recover.展开更多
文摘Studies were performed in 20 patients with breast cancer, who received 26 cycles of high-dose cisplatin (100 mg/m2, IV. drip). In twenty-five cycles of them urinary Alb, IgG and NAG showed abnormal values. The patients were divided into low-nephrotoxicity and high-nephrotoxicity groups by the degree of renal dysfunction. Thirty-five percent of the patients exhibited high-nephrotoxicity. These patients had significantly higher plasma and/ or urinary Pt peak levels during cisplatin (CP) infusion than did low-nephrotoxicity. 70 - 80% of the patients developed significant nephrotoxicity when urinary Pt peak level rose up to 40 fig/ml or plasma Pt peak level >4 μg/ml. It is quite important to reduce nephrotoxicity that urinary Pt level is controlled below 40 μg/ml and plasma Pt level <4 μg/ml. It is suggested that urine output should be maintained over 300 ml/hr during 2 hours before and after the end of infusion and >100 ml/hr during 3 days after the infusion. That may keep the nephrotoxicity of CP in less serious degree and easy to recover.
